• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    DCAT Week ’19

    Temperature-Controlled Logistics

    Reducing Pill Burden

    Nasal Drug Delivery

    AI in Pharma: Transforming Data into Drugs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Nestlé Health Licenses Codexis’ CDX-6114

    SK, Arvelle Sign $530M Deal for Antiepileptic Drug

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Progenics Launches Mfg. Ops in NJ

    Charles River to Pay $510M for Citoxlab
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Progenics Launches Mfg. Ops in NJ

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour

    Haselmeier Acquires Drug Manufacturing License

    Emerald Health, Lonza Enter Large-Scale Mfg. Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour

    Recipharm Facilities Ready for EU Serialization

    Andrew Alliance, Sartorius Launch Research Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nestlé Health Licenses Codexis’ CDX-6114

    Personalized Medicine: Getting More Out of Clinical Trials

    SK, Arvelle Sign $530M Deal for Antiepileptic Drug

    Charles River to Pay $510M for Citoxlab

    West, Swissfillon Enter Drug Delivery Partnership
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Former FDA Senior Executives Join PAREXEL

    Top Global Pharma Company to Implement ValGenesis' VLMS

    WCG, Prudentia Enter Pharmacovigilance Alliance

    ValGenesis VLMS Chosen to Digitize Validation Process

    Serialization Compliance: Understanding the Challenges
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Federal Equipment Company

    Aphena Pharma Solutions, Inc.

    Reed-Lane, Inc.

    Alcami

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Baxter BioPharma Solutions

    Ajinomoto Bio-Pharma Services

    Federal Equipment Company

    Emergent BioSolutions, Inc.
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    FDI Green Light Sets The Stage

    M&A activity and outsourcing to gather pace

    Related CONTENT
    • Blackstone Group Acquires Klockner
    • Pfizer To Sell Capsugel Unit for $2.4B
    • Capsugel to Acquire Bend Research
    • PRA, RPS Complete Merger
    • Consolidation in Outsourcing
    S. Harachand, Contributing Editor09.08.16
    In what could be termed as the largest buyout in the Indian pharma space this year, Shanghai Fosun Pharmaceutical Group signed a deal to acquire an 86 percent stake in Gland Pharma, an injectables maker, in July. The nearly $1.3 billion buy of the Hyderabad, south India-based firm will not only provide Fosun with a portfolio of injectables, but help beef up its manufacturing prowess too.

    Gland Pharma operates four facilities manufacturing injectable medicines. With established strengths in APIs, Fosun can look for vertically integrating the production process.

    Privately held Gland Pharma has secured approvals from U.S. and European regulators for making a range of ampoules, lyophilized vials, pre-filled syringes, dry powders, infusions and ophthalmic solutions.

    Fosun, which was looking for assets in developing markets such as India, said the deal with Gland Pharma would expedite the Chinese major’s internationalization process.

    The 86 percent of Gland Pharma include a 49 percent stake from the founder P VN Raju and his family and a 37 percent holding from the New York-based private equity firm Kohlberg Kravis Roberts & Co. KKR bought the stake in Gland Pharma in 2014 for $200 million. In the meantime, the founder family will continue to hold a 10 percent stake in the company.

    Attracting capital
    The Gland-Fosun deal evinced special interest in the investors as being the first major cross-border acquisition and happened soon after India announced sweeping changes to its foreign direct investment (FDI) policy.

    This June, the Union Cabinet introduced a slew of measures to further liberalize the nation’s investment climate allowing 100% FDI in several key sectors, including defense, civil aviation and food processing.

    To facilitate further investments in the pharma sector, the government cleared the decks by removing a disputed clause requiring prior government approval for up to 74 percent FDI in existing companies. Investors often found this condition of obtaining approval from government agencies like Foreign Investment Promotion Board cumbersome as the bureaucratic process led to inordinate delays.

    The easing up of the policy now makes it possible to fully own Indian pharma companies or the so-called brownfield units and the investors need to seek permission for any FDI beyond 74 percent. Previously, FDI above 49 percent required a government nod. However, a no-holds-bar 100 percent FDI is allowed under automatic route for greenfield pharma.

    The government is aiming at attracting required capital, international best practices and latest technologies in the pharma sector by permitting 74 percent FDI under automatic route in brownfield pharmaceutical sector, according to Nirmala Sitharaman, India’s Minister of State in the Ministry of Commerce & Industry.

    India’s FDI inflows grew 29 percent to $40.46 billion in the fiscal year ended in March, according the data issued by the ministry.

    CRAMS to soar
    Industry bodies hailed the move saying that the decision to relax FDI norms is a bold step in the right direction. The long overdue revision of FDI cap has immense possibilities for setting up manufacturing facilities, obtaining technologies and capabilities and generating high skilled employment.

    FDI would provide the Indian pharma industry access to more funds for investing in R&D, which in turn, will lead to the creation of more IPR, according to DS Rawat, secretary general of ASSOCHAM, apex industry association.

    Organization of Indian Pharmaceutical Producers of India, a grouping of mostly MNC firms, opined that new measures would enable enhanced investments in the form of M&A activity from the multinational companies. Foreign firms have been lobbying hard seeking revision to allow 100 percent FDI under the automatic route for both new and existing companies.

    Promoting the “Made in India” initiative through relaxed FDI norms could spur the growth of the outsourcing segment, especially manufacturing. The contract research and manufacturing (CRAMS) sector may see a lot of action as flexible FDI could motivate companies looking for full control, experts say.

    Small cap firms, however, are of the view that FDI in brownfield pharma would not facilitate asset creation and long-term growth of Indian pharma.

    Meanwhile, medicine access civil groups see red in a widening FDI base. MNCs’ increasing control over India’s generic industry could potentially lead to more pressure on IP and eventually affect the affordability of lifesaving medicines, they fear.


    S. Harachand
    Contributing Editor

    S. Harachand is a pharmaceutical journalist based in Mumbai. He can be reached at harachand@gmail.com.
    Suggested For You
    Indian Generic Firms  Expand Biosimilar Portfolios Indian Generic Firms Expand Biosimilar Portfolios
    WHO Lauds India’s Vaccine Safety WHO Lauds India’s Vaccine Safety
    Booster Dose for Device Makers Booster Dose for Device Makers
    API Makers Speed Expansion API Makers Speed Expansion
    Lonza to Acquire Capsugel Lonza to Acquire Capsugel
    India On GMP Drive India On GMP Drive
    Discovery: The New Mantra Discovery: The New Mantra
    Betting Big On Injectables Betting Big On Injectables
    Recipharm Completes Serialization Solution in China Recipharm Completes Serialization Solution in China
    Indian Government Forms Responsible Healthcare Trust Indian Government Forms Responsible Healthcare Trust
    Consolidation in Outsourcing Consolidation in Outsourcing
    PRA, RPS Complete Merger PRA, RPS Complete Merger
    Capsugel to Acquire Bend Research Capsugel to Acquire Bend Research
    Pfizer To Sell Capsugel Unit for $2.4B Pfizer To Sell Capsugel Unit for $2.4B
    Blackstone Group Acquires Klockner Blackstone Group Acquires Klockner

    Related Columns

    • Drugs as...Fashion?

      Drugs as...Fashion?

      Fashion finds its way into pharma whether you like it or not
      Ben Locwin 01.25.19

    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18

    • “Clinically Speaking”

      “Clinically Speaking”

      Let’s get back to what it means to do things “clinically”
      Ben Locwin 11.14.18


    • Analytical Services | Laboratory Testing
      Possibly Time for a New Paradigm

      Possibly Time for a New Paradigm

      Or, why the chicken should cross the road
      Emil W. Ciurczak, DoraMaxx Consulting 10.10.18

    • No, Your Neighbors and Facebook Friends Don’t Know Anything About Health and Wellness

      No, Your Neighbors and Facebook Friends Don’t Know Anything About Health and Wellness

      And by the way, get your flu shot
      Ben Locwin 10.10.18

    • An “All-You-Can-Eat” Buffet for Excellence

      An “All-You-Can-Eat” Buffet for Excellence

      Or, touching on almost all editorial subjects for the month
      Emil W. Ciurczak, DoraMaxx Consulting 09.11.18


    • Pharma Future

      Pharma Future

      Where are we now? What’s next?
      Ben Locwin 09.11.18

    • CDMOs and Drug Shortages

      CDMOs and Drug Shortages

      A new proposal helps create a manufacturing backstop
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 09.11.18

    • Who is Responsible for Manufacturing Technology Innovation?

      Who is Responsible for Manufacturing Technology Innovation?

      Pharma’s future lies in putting innovations in the hands of innovators, not the regulators
      Girish Malhotra, Contributing Editor 09.11.18


    • Biopharmaceuticals Outsourcing Slows

      Biopharmaceuticals Outsourcing Slows

      Manufacturers are shifting focus
      Eric S. Langer, BioPlan Associates 09.11.18

    • The Right To Try

      The Right To Try

      A slippery slope that represents the complexity of being human
      Ben Locwin 07.20.18

    • Analytical Services | Laboratory Testing
      The Times, They Are a-Changin’

      The Times, They Are a-Changin’

      For contract organizations and generics, for sure
      Emil W. Ciurczak, DoraMaxx Consulting 07.20.18

    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18

    • Information Technology
      Putting Data Integrity in Quality Agreements

      Putting Data Integrity in Quality Agreements

      With growing regulatory scrutiny, sponsors are focusing more on data integrity in supplier quality agreements.
      Robert Marohn, ClinLogic, LLC 06.12.18

    • Regulatory Affairs
      India raises bar for clinical trial oversight

      India raises bar for clinical trial oversight

      New guidelines to bolster institutional ethical committees
      S. Harachand, Contributing Editor 05.08.18

    Breaking News
    • Nestlé Health Licenses Codexis’ CDX-6114
    • SK, Arvelle Sign $530M Deal for Antiepileptic Drug
    • GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers
    • Progenics Launches Mfg. Ops in NJ
    • Charles River to Pay $510M for Citoxlab
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • DCAT Week ’19
    • Temperature-Controlled Logistics
    • Reducing Pill Burden
    • Nasal Drug Delivery
    • AI in Pharma: Transforming Data into Drugs
    • Digitization: Pharma 4.0
    • Serialization Compliance: Understanding the Challenges
    • FDA & Data Integrity
    • Rising Demand for Lyophilized Products
    • Future Trends in the CDMO Space
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login